Next-Generation Stroke Biomarkers: Bridging the Gap Between Innovation and Translation
Journal of Clinical Medicine · 12.08.2026 · 15 (16) · 6249
DOI: 10.3390/jcm15166249 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 12.08.2026. Verfasst von Emilia Conti und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Optics, National Research Council, Via Nello Carrara 1, 50019 Sesto Fiorentino, Italy. Die Arbeit nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cassa di Risparmio di Firenze Foundation, Fondazione Cassa di Risparmio di Firenze.
Themen: Schlaganfall
Abstract (Originalsprache)
The identification of valid biomarkers for ischemic stroke would greatly benefit not only diagnostic and prognostic assessment but also the development of new therapies. The development of omics technologies has made it possible to explore various perspectives of the pathophysiology of ischemic stroke, in particular genomics, transcriptomics, proteomics and metabolomics, and well-known clinical variables, such as hypertension, diabetes, heart diseases, and many others. Omics-based research has produced a mass of data evidencing candidate biomarkers at different stages in the disease process. However, further scientific evidence must be presented and affordable, and rapid detection techniques developed before these technologies can be usefully applied to the clinical setting of stroke. Here, we aim to provide stroke clinicians with an updated overview of the contribution of these emerging technologies in the individuation of diagnostic and prognostic biomarkers and the development of specifically targeted therapies. Cross-fertilization (translation and reverse translation) between preclinical and clinical research is of particular relevance in the identification of stroke biomarkers. We believe it is useful to provide, in parallel, an updated review of omics investigations using stroke rodent models. This review presents a detailed discussion of the state of the art, focusing on the strengths and limitations of the individual technologies and an outline of the promising, most recent results of both clinical and preclinical research in this field related to stroke.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Institute of Optics, National Research Council, Via Nello Carrara 1, 50019 Sesto Fiorentino, Italy.
- European Laboratory for Non Linear Spectroscopy (LENS), Via Nello Carrara 1, 50019 Sesto Fiorentino, Italy.
- Neuroscience Institute, National Research Council, Via Madonna del Piano 10, 50019 Sesto Fiorentino, Italy.
- Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134 Firenze, Italy.
- Department of Physics and Astronomy, University of Florence, Via Sansone 1, 50019 Sesto Fiorentino, Italy.
ORCID-Profile: Emilia Conti, Marzia Baldereschi, Antonio Di Carlo, Anna Maria Gori, Betti Giusti
Förderung
- Cassa di Risparmio di Firenze Foundation
- Fondazione Cassa di Risparmio di Firenze
Zitieren
APA
Conti, E., Baldereschi, M., Di Carlo, A., Barbieri, G., Pavone, F. S., Gori, A. M., & Giusti, B. (2026). Next-Generation Stroke Biomarkers: Bridging the Gap Between Innovation and Translation. Journal of Clinical Medicine, 15(16), 6249. https://doi.org/10.3390/jcm15166249
Vancouver
Conti E, Baldereschi M, Di Carlo A, Barbieri G, Pavone FS, Gori AM, et al. Next-Generation Stroke Biomarkers: Bridging the Gap Between Innovation and Translation. Journal of Clinical Medicine. 2026;15(16):6249. doi:10.3390/jcm15166249
BibTeX
@article{Conti2026,
author = {Conti, Emilia and Baldereschi, Marzia and Di Carlo, Antonio and Barbieri, Giulia and Pavone, Francesco Saverio and Gori, Anna Maria and Giusti, Betti},
title = {Next-Generation Stroke Biomarkers: Bridging the Gap Between Innovation and Translation},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {16},
pages = {6249},
doi = {10.3390/jcm15166249}
}
EUVIMED